Literature DB >> 19874265

A neurotrophic rationale for the therapy of neurodegenerative disorders.

H Uri Saragovi1, Edith Hamel, Adriana Di Polo.   

Abstract

The concept and rationale for neuroprotection are presented. Several examples of small molecule neurotrophic agents with favourable drug-like and pharmacological properties are shown. Compound efficacy in acute neurodegenerative models (optic nerve axotomy) and chronic neurodegenerative models (glaucoma, age-associated cognitive impairment, Alzheimer's Disease) are evaluated and discussed. Targeting neurotrophin receptors with ligands that activate survival pathways or inhibit death pathways is an alternative worth pursuing.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19874265     DOI： 10.2174/156720509789207912

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN： 1567-2050            Impact factor:   3.498


  18 in total

1.  Role of the conformational versatility of the neurotrophin N-terminal regions in their recognition by Trk receptors.

Authors:  Francesca Stanzione; Luciana Esposito; Antonella Paladino; Carlo Pedone; Giancarlo Morelli; Luigi Vitagliano
Journal:  Biophys J       Date:  2010-10-06       Impact factor: 4.033

2.  Wnt signaling as a potential therapeutic target for frontotemporal dementia.

Authors:  Zeljka Korade; Károly Mirnics
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

3.  Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors.

Authors:  Kiren Ubhi; Edward Rockenstein; Michael Mante; Chandra Inglis; Anthony Adame; Christina Patrick; Kristen Whitney; Eliezer Masliah
Journal:  J Neurosci       Date:  2010-05-05       Impact factor: 6.167

Review 4.  Neurotrophins in lung health and disease.

Authors:  Ys Prakash; Michael A Thompson; Lucas Meuchel; Christina M Pabelick; Carlos B Mantilla; Syed Zaidi; Richard J Martin
Journal:  Expert Rev Respir Med       Date:  2010-06       Impact factor: 3.772

5.  Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy.

Authors:  Kiren Ubhi; Chandra Inglis; Michael Mante; Christina Patrick; Anthony Adame; Brian Spencer; Edward Rockenstein; Verena May; Juergen Winkler; Eliezer Masliah
Journal:  Exp Neurol       Date:  2012-01-16       Impact factor: 5.330

Review 6.  Intrinsic axonal degeneration pathways are critical for glaucomatous damage.

Authors:  Gareth R Howell; Ileana Soto; Richard T Libby; Simon W M John
Journal:  Exp Neurol       Date:  2012-01-18       Impact factor: 5.330

7.  Neuron-targeted caveolin-1 improves neuromuscular function and extends survival in SOD1G93A mice.

Authors:  Atsushi Sawada; Shanshan Wang; Minyu Jian; Joseph Leem; Jesse Wackerbarth; Junji Egawa; Jan M Schilling; Oleksandr Platoshyn; Alice Zemljic-Harpf; David M Roth; Hemal H Patel; Piyush M Patel; Martin Marsala; Brian P Head
Journal:  FASEB J       Date:  2019-03-20       Impact factor: 5.191

Review 8.  Brain-derived neurotrophic factor in the airways.

Authors:  Y S Prakash; Richard J Martin
Journal:  Pharmacol Ther       Date:  2014-02-19       Impact factor: 12.310

9.  In glaucoma the upregulated truncated TrkC.T1 receptor isoform in glia causes increased TNF-alpha production, leading to retinal ganglion cell death.

Authors:  Yujing Bai; ZhiHua Shi; Yehong Zhuo; Jing Liu; Andrey Malakhov; Eunhwa Ko; Kevin Burgess; Henry Schaefer; Pedro F Esteban; Lino Tessarollo; H Uri Saragovi
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06-23       Impact factor: 4.799

10.  A Pro-Nerve Growth Factor (proNGF) and NGF Binding Protein, α2-Macroglobulin, Differentially Regulates p75 and TrkA Receptors and Is Relevant to Neurodegeneration Ex Vivo and In Vivo.

Authors:  Pablo F Barcelona; H Uri Saragovi
Journal:  Mol Cell Biol       Date:  2015-07-27       Impact factor: 4.272
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.